Aerovate Therapeutics, Inc.
AVTE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $53 | $64 | $39 | $15 |
| G&A Expenses | $21 | $17 | $15 | $8 |
| SG&A Expenses | $21 | $17 | $15 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $75 | $81 | $53 | $23 |
| Operating Income | -$75 | -$81 | -$53 | -$23 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $6 | $2 | $0 |
| Pre-Tax Income | -$70 | -$75 | -$51 | -$23 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$70 | -$76 | -$52 | -$23 |
| % Margin | – | – | – | – |
| EPS | -2.44 | -2.87 | -2.1 | -1.87 |
| % Growth | 15% | -36.7% | -12.3% | – |
| EPS Diluted | -2.44 | -2.87 | -2.1 | -1.87 |
| Weighted Avg Shares Out | 29 | 26 | 24 | 24 |
| Weighted Avg Shares Out Dil | 29 | 26 | 24 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $2 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$74 | -$81 | -$53 | -$23 |
| % Margin | – | – | – | – |